In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version.
Additional information
The online version of the original article can be found at 10.1038/nrd.2017.91
Rights and permissions
About this article
Cite this article
Hutchings, C., Koglin, M., Olson, W. et al. Erratum: Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov 16, 661 (2017). https://doi.org/10.1038/nrd.2017.173
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.173
This article is cited by
-
Targeting chemokines for acute lymphoblastic leukemia therapy
Journal of Hematology & Oncology (2021)
-
Kaposiform hemangioendothelioma: current knowledge and future perspectives
Orphanet Journal of Rare Diseases (2020)
-
Structural insights into G-protein-coupled receptor allostery
Nature (2018)
-
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Nature Reviews Drug Discovery (2018)
-
Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery Strategies
BioDrugs (2018)
